公开(公告)号：US20130018033A1

公开(公告)日：2013-01-17

申请号：US13393116

申请日：2010-08-27

Applicant: Ignacio Aliagas ,  Stefan Gradl ,  Janet Gunzner ,  Wendy Lee ,  Simon Mathieu ,  Joachim Rudolph ,  Zhaoyang Wen ,  Guiling Zhao ,  Alexandre J. Buckmelter ,  Jonas Grina ,  Joshua D. Hansen ,  Ellen Laird ,  David Moreno ,  Li Ren ,  Steven Mark Wenglowsky

Inventor： Ignacio Aliagas ,  Stefan Gradl ,  Janet Gunzner ,  Wendy Lee ,  Simon Mathieu ,  Joachim Rudolph ,  Zhaoyang Wen ,  Guiling Zhao ,  Alexandre J. Buckmelter ,  Jonas Grina ,  Joshua D. Hansen ,  Ellen Laird ,  David Moreno ,  Li Ren ,  Steven Mark Wenglowsky

IPC: A61K31/517 ,  C07D471/04 ,  A61K31/519 ,  C07D405/12 ,  A61P35/02 ,  C07D401/12 ,  C07D413/12 ,  A61K31/5377 ,  C07D239/72 ,  A61P35/00 ,  C07D239/94 ,  C07D403/12

CPC classification number: C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D471/04

Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract translation: 式I化合物可用于抑制Raf激酶。 公开了使用式I化合物和立体异构体，互变异构体，前药和其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20170216262A1

公开(公告)日：2017-08-03

申请号：US15473110

申请日：2017-03-29

Applicant: Kenneth W. BAIR ,  Timm R. BAUMEISTER ,  Peter DRAGOVICH ,  Xiongcai LIU ,  Snahel PATEL ,  Po-Wai YUEN ,  Mark ZAK ,  Guiling ZHAO ,  Yamin ZHANG ,  Xiaozhang ZHENG

Inventor： Kenneth W. BAIR ,  Timm R. BAUMEISTER ,  Peter DRAGOVICH ,  Xiongcai LIU ,  Snahel PATEL ,  Po-Wai YUEN ,  Mark ZAK ,  Guiling ZHAO ,  Yamin ZHANG ,  Xiaozhang ZHENG

IPC: A61K31/438 ,  C07D471/04 ,  C07D495/04 ,  C07D487/04 ,  A61K31/519 ,  C07D491/048 ,  A61K31/496 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/513 ,  A61K31/541 ,  A61K31/506 ,  A61K31/501 ,  C07D519/00 ,  A61K45/06

CPC classification number: C07D519/00 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04

Abstract: Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

公开(公告)号：US08354420B2

公开(公告)日：2013-01-15

申请号：US13150929

申请日：2011-06-01

Applicant: Charles Baker-Glenn ,  Daniel Jon Burdick ,  Mark Chambers ,  Bryan K. Chan ,  Huifen Chen ,  Anthony Estrada ,  Janet Gunzner-Toste ,  Daniel Shore ,  Zachary Sweeney ,  Shumei Wang ,  Guiling Zhao

Inventor： Charles Baker-Glenn ,  Daniel Jon Burdick ,  Mark Chambers ,  Bryan K. Chan ,  Huifen Chen ,  Anthony Estrada ,  Janet Gunzner-Toste ,  Daniel Shore ,  Zachary Sweeney ,  Shumei Wang ,  Guiling Zhao

IPC: A61K31/505 ,  C07D239/28

CPC classification number: C07D413/14 ,  C07D403/14 ,  C07D413/12 ,  C07D473/16 ,  C07D498/06 ,  C07D498/08

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Abstract translation: 式I化合物或其药学上可接受的盐，其中m，n。 X，R 1，R 2，R 3，R 5，R 6和R 7如本文所定义。 还公开了制备化合物和使用该化合物治疗与LRRK2受体（例如帕金森病）相关的疾病的方法。

公开(公告)号：US20110301141A1

公开(公告)日：2011-12-08

申请号：US13150929

申请日：2011-06-01

Applicant: Charles Baker-Glenn ,  Daniel Jon Burdick ,  Mark Chambers ,  Bryan K. Chan ,  Huifen Chen ,  Anthony Estrada ,  Janet Gunzner-Toste ,  Daniel Shore ,  Zachary Sweeney ,  Shumei Wang ,  Guiling Zhao

Inventor： Charles Baker-Glenn ,  Daniel Jon Burdick ,  Mark Chambers ,  Bryan K. Chan ,  Huifen Chen ,  Anthony Estrada ,  Janet Gunzner-Toste ,  Daniel Shore ,  Zachary Sweeney ,  Shumei Wang ,  Guiling Zhao

IPC: A61K31/5377 ,  C07D401/12 ,  C07D401/14 ,  A61P25/16 ,  A61K31/506 ,  A61K31/5386 ,  A61K31/553 ,  C07D413/12 ,  C07D403/12

CPC classification number: C07D413/14 ,  C07D403/14 ,  C07D413/12 ,  C07D473/16 ,  C07D498/06 ,  C07D498/08

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Abstract translation: 式I化合物或其药学上可接受的盐，其中m，n。 X，R 1，R 2，R 3，R 5，R 6和R 7如本文所定义。 还公开了制备化合物和使用该化合物治疗与LRRK2受体（例如帕金森病）相关的疾病的方法。

公开(公告)号：US20080261902A1

公开(公告)日：2008-10-23

申请号：US12157810

申请日：2008-06-13

Applicant: Jinhua Zhao ,  Hui Kang ,  Weizhen Zeng ,  Lijuan Zhang ,  Dan Zhu ,  Chuangui Huang ,  Hong Chen ,  Hanlin Feng ,  Lin Yu ,  Xuliang Huang ,  Guiling Zhao ,  Kesen Zhao

Inventor： Jinhua Zhao ,  Hui Kang ,  Weizhen Zeng ,  Lijuan Zhang ,  Dan Zhu ,  Chuangui Huang ,  Hong Chen ,  Hanlin Feng ,  Lin Yu ,  Xuliang Huang ,  Guiling Zhao ,  Kesen Zhao

IPC: A61K31/7034 ,  A61P7/04

CPC classification number: A61K31/7034 ,  A61K9/0019

Abstract: A composition includes polydatin and solvent for dissolving the polydatin, wherein the solvent comprises alcohol in a range between 40 and 95% by volume, propanediol in a range between 0 and 60% by volume, and water in remaining volume. The concentration of the polydatin must be at least 6 mg/ml. The composition has good stability in cold preservation. The composition is in a pharmaceutically acceptable administrative form selected from the group consisting of an intravenous injection, and intramuscular injection, an oral administration, a spray solution, and an aerosol form.

Abstract translation: 一种组合物包括用于溶解多聚糖的多聚糖和溶剂，其中该溶剂包含体积范围为40至95体积％的丙二醇，体积为0至60体积％的丙二醇和剩余体积的水。 多聚糖的浓度必须至少为6 mg / ml。 该组合物在冷藏中具有良好的稳定性。 组合物是选自静脉内注射和肌内注射，口服给药，喷雾溶液和气雾剂形式的药学上可接受的行政形式。

公开(公告)号：US20080009453A1

公开(公告)日：2008-01-10

申请号：US10492405

申请日：2003-08-04

Applicant: Jinhua Zhao ,  Hui Kang ,  Kesen Zhao ,  Xuliang Huang ,  Guiling Zhao ,  Jing Li ,  Hanlin Feng ,  Guanghui Yao ,  Qian Yao ,  Shengzhao Lin ,  Qi Zhou

Inventor： Jinhua Zhao ,  Hui Kang ,  Kesen Zhao ,  Xuliang Huang ,  Guiling Zhao ,  Jing Li ,  Hanlin Feng ,  Guanghui Yao ,  Qian Yao ,  Shengzhao Lin ,  Qi Zhou

IPC: A61K31/7034 ,  A61P7/00 ,  A61P9/00

CPC classification number: A61K31/7032

Abstract: The invention discloses pharmaceutical compositions containing polydatin or its pharmaceutically acceptable salts with the effect of improving microcirculation, and their application in preparing drugs which can improve microcirculation. The compositions are an non-gastrointestinal injection preparation, the preparation can be an aqueous solution which have pH 7.0-10.0 comprising 5-50% propandiol. The dosage forms of the compositions may be lyophilizing powder injection, oral form, suppository of procto-administration and other forms of administrations comprising unguent, ointment, paste film coating and the like. The compositions may be used to treat and/or prevent diseases related to microcirculation blockage. The unit form may contain 1-1000 mg polydatin or its derivatives. The invention solves the problem of using polydatin to improve microcirculation. The composition of the invention can be used in treating shock, cardiac and cerebrovascular diseases, diseases of sense organs, diabetes complication, vaculitis related to blockage of blood vessel, hemorrhoid related to circulation obstruction, skin injury and burn.

Abstract translation: 本发明公开了含有多糖或其药学上可接受的盐的药物组合物，其具有改善微循环的作用，以及它们在制备可改善微循环的药物中的应用。 组合物是非消化道注射制剂，该制剂可以是含有5-50％丙二醇的pH 7.0-10.0的水溶液。 组合物的剂型可以是冷冻干燥粉末注射剂，口服剂型，直接给药栓剂和包括无制剂，软膏剂，糊剂涂膜等的其它形式的给药。 组合物可用于治疗和/或预防与微循环阻塞有关的疾病。 单位形式可能含有1-1000 mg多聚糖或其衍生物。 本发明解决了使用多聚糖改善微循环的问题。 本发明的组合物可用于治疗休克，心脑血管疾病，感觉器官疾病，糖尿病并发症，与血管阻塞有关的空洞炎，与循环障碍相关的痔疮，皮肤损伤和烧伤。